News
Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...
The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...
Make like a mattress company and sell shots and pills straight to the consumer.It’s a strategy that companies such as Hims & Hers Health and Ro have pursued for years, mostly to sell inexpensive, ...
By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...
An Anthem Blue Cross subscriber is suing the health insurer, alleging she was wrongfully denied coverage for Zepbound for weight management because she was no longer considered morbidly obese. Alicia ...
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Eli Lilly for allegedly bribing and ...
Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...
Attorney General Ken Paxton filed a lawsuit this week against Eli Lilly for allegedly bribing Texas health care providers to ...
Are you a TRICARE beneficiary taking a drug for weight loss—such as a GLP-1 medication like Zepbound or Wegovy? Do you have ...
A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.
Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...
Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results